1. Home
  2. JYNT vs CGEN Comparison

JYNT vs CGEN Comparison

Compare JYNT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.37

Market Cap

138.0M

Sector

Miscellaneous

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.05

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
CGEN
Founded
2010
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.0M
148.7M
IPO Year
2014
2001

Fundamental Metrics

Financial Performance
Metric
JYNT
CGEN
Price
$8.37
$2.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$17.00
$4.00
AVG Volume (30 Days)
63.3K
319.5K
Earning Date
03-12-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
133.93
N/A
EPS
0.19
N/A
Revenue
$117,696,356.00
N/A
Revenue This Year
$12.23
N/A
Revenue Next Year
N/A
$112.37
P/E Ratio
$44.63
N/A
Revenue Growth
15.49
N/A
52 Week Low
$7.50
$1.13
52 Week High
$13.47
$2.38

Technical Indicators

Market Signals
Indicator
JYNT
CGEN
Relative Strength Index (RSI) 42.20 49.24
Support Level $8.14 $1.47
Resistance Level $8.67 $2.35
Average True Range (ATR) 0.32 0.10
MACD 0.02 -0.03
Stochastic Oscillator 29.48 8.82

Price Performance

Historical Comparison
JYNT
CGEN

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: